TREM2 and Alzheimer disease: However, the therapeutic application of this approach has proven challenging, as exemplified by the recent failure of the TREM2-targeting monoclonal antibody AL002 in the phase 2 INVOKE-2 trial for early-stage AD (ClinicalTrials.gov identifier NCT04592874).